高敏肌钙蛋白I与临床风险评分在疑似急性冠脉综合征患者中的应用
本研究在1935例疑似急性冠脉综合征患者中评估两种排除路径单独或联合临床风险评分的表现。欧洲心脏病学会3小时路径排除70%患者,阴性预测值97.9%,联合HEART评分≤3可将阴性预测值提高至99.7%但排除比例降至25%;High-STEACS路径排除65%,阴性预测值99.7%,风险评分未提高其安全性但使排除比例减半。
要点
- 欧洲心脏病学会3小时路径联合HEART评分≤3可提高安全性但降低排除比例。
- High-STEACS路径阴性预测值达99.7%,风险评分未进一步改善安全性。
- 在低阈值排除路径中加用风险评分使排除比例减半而不改善安全性。
核心结论
- 临床风险评分显著提高了依赖单一99百分位阈值排除心肌梗死的欧洲心脏病学会3小时路径的安全性。
- 在采用低阈值排除心肌梗死的High-STEACS路径中,风险评分使排除比例减半而未提高安全性。
研究设计与样本
- 研究纳入1935例疑似急性冠脉综合征患者,评估两种排除路径单独或联合TIMI、GRACE、EDACS或HEART评分的表现。
- 欧洲心脏病学会3小时路径使用单一99百分位诊断阈值,High-STEACS路径采用<5 ng/L排除和>99百分位确认的不同阈值。
主要发现
- 主要终点(就诊时或30天内心肌梗死或心源性死亡)发生于14.3%(276/1935)的患者。
- 欧洲心脏病学会路径排除70%患者,遗漏27例事件,阴性预测值97.9%(95% CI 97.1-98.6)。
- 联合HEART评分≤3使欧洲心脏病学会路径排除比例降至25%,阴性预测值提高至99.7%(95% CI 99.0-100;P<0.001)。
- High-STEACS路径排除65%患者,遗漏3例事件,阴性预测值99.7%(95% CI 99.4-99.9)。
- 无风险评分改善High-STEACS路径的阴性预测值,但所有评分均降低排除比例(24%至47%;P<0.001)。
关键数值与推荐
- TIMI低危定义为0或1分,GRACE低危定义为≤108,EDACS低危定义为<16,HEART低危定义为≤3。
- 欧洲心脏病学会3小时路径采用99百分位单一阈值,High-STEACS路径采用<5 ng/L排除和>99百分位确认。
临床怎么用
- 对于疑似急性冠脉综合征患者,采用欧洲心脏病学会3小时路径时可联合HEART评分≤3以提高安全性,但需注意排除比例降低。
- 采用High-STEACS路径时加用临床风险评分可能减少被排除的患者数量而不改善安全性,需权衡利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-sensitivity cardiac troponin assays can help to identify patients who are at low risk of myocardial infarction in the emergency department. We aimed to determine whether the addition of clinical risk scores would improve the safety of early rule-out pathways for myocardial infarction. METHODS: In 1935 patients with suspected acute coronary syndrome, we evaluated the safety and efficacy of 2 rule-out pathways alone or in conjunction with low-risk TIMI (Thrombolysis In Myocardial Infarction) (0 or 1), GRACE (Global Registry of Acute Coronary Events) (≤108), EDACS (Emergency Department Assessment of Chest Pain Score) (<16), or HEART (History, ECG, Age, Risk factors, Troponin) (≤3) scores. The European Society of Cardiology 3-hour pathway uses a single diagnostic threshold (99th percentile), whereas the High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome) pathway applies different thresholds to rule out (<5 ng/L) and rule in (>99th percentile) myocardial infarction. RESULTS: Myocardial infarction or cardiac death during the index presentation or at 30 days occurred in 14.3% of patients (276/1935). The European Society of Cardiology pathway ruled out 70%, with 27 missed events giving a negative predictive value of 97.9% (95% CI, 97.1-98.6). The addition of a HEART score ≤3 reduced the proportion ruled out by the European Society of Cardiology pathway to 25% but improved the negative predictive value to 99.7% (95% CI, 99.0-100; P<0.001). The High-STEACS pathway ruled out 65%, with 3 missed events for a negative predictive value of 99.7% (95% CI, 99.4-99.9). No risk score improved the negative predictive value of the High-STEACS pathways, but all reduced the proportion ruled out (24% to 47%; P<0.001 for all). CONCLUSIONS: Clinical risk scores significantly improved the safety of the European Society of Cardiology 3-hour pathway, which relies on a single cardiac troponin threshold at the 99th percentile to rule in and rule out myocardial infarction. Where lower thresholds are used to rule out myocardial infarction, as applied in the High-STEACS pathway, risk scores halve the proportion of patients ruled out without improving safety. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01852123.
引用
- Chapman AR, Hesse K, Andrews J, et al. High-Sensitivity Cardiac Troponin I and Clinical Risk Scores in Patients With Suspected Acute Coronary Syndrome. Circulation. 2018. PMID: 30354460. doi:10.1161/CIRCULATIONAHA.118.036426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。